Pfizer Inc. (NYSE:PFE) is one of Jim Cramer\u2019s Hottest GLP-1 and Weight Loss Stock Picks<\/strong>.<\/p>\n Pfizer Inc. (NYSE:PFE) is one of the largest pharmaceutical companies in the world. It operates in the weight loss drug market by developing a treatment that will be administered only once a month. The shares are up by 6.7% over the past year and by 25% since Cramer discussed the firm on Mad Money. One notable movement in Pfizer Inc. (NYSE:PFE)\u2019s shares came between September 29th and October 1st, when they gained 14%. A key announcement that occurred during this time period saw the firm announce that it would lower drug prices under Medicaid to bring them in line with those in developing countries after an agreement with President Trump and be part of the Trump administration\u2019s TrumpRx initiative. Year-to-date, Pfizer Inc. (NYSE:PFE)\u2019s shares are up by 7.4%. However, on February 3rd, the shares closed 3.3% lower after the firm reported its fiscal fourth quarter earnings report. The results saw Pfizer Inc. (NYSE:PFE) post $17.6 billion in revenue and $0.66 in adjusted earnings per share. Here is what Cramer had said about the firm in April 2025:<\/p>\n \u201cWell, let me tell you something\u2026 right now, we have a government that is trying to figure out whether it\u2019s going to tax the heck out of drug companies, raise tariffs outta drug companies or not. I can\u2019t make a prediction anymore. It yields 8%. Normally I say fine, but you know what? Let\u2019s say you decide, you know what, we need big tariffs on Pfizer. You\u2019ll say, wow, I\u2019m buying that stock at 18 rather than 21. So I\u2019m going to have to say, pass.\u201d<\/p>\n<\/blockquote>\n Piotr Kowalski\/Shutterstock.com<\/p>\n While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/strong>.<\/p>\n\n
<\/div>\n<\/div>